Core Viewpoint - Synthetic biology is poised to reshape the world through innovations such as novel antibody drugs, mRNA vaccines, and DNA data storage, with DNA synthesis as the foundational technology [1] Industry Status: Supply and Demand "Time Lag" - The high-throughput DNA synthesis sector in China is experiencing a "time lag" between supply and demand, with various applications yet to fully materialize [4] Challenges and Opportunities on the Marathon Track - Increased capital influx has led to intense competition focused on capacity and pricing, hindering the establishment of true technological barriers and sustainable business models [5] - The company aims to be a "marathon runner" in the industry, focusing on long-term value creation and resilience through economic cycles [5] Performance Priority and Cost Optimization - The company prioritizes performance as the cornerstone of technological value, ensuring high-quality synthesis before pursuing cost reductions through innovation and process optimization [6] Robust Operational System: Building a Value-Driven Moat - Long-term development is rooted in core value and robust operational capabilities, with a focus on customer value and a resilient operational system [7] - The company controls the entire supply chain from raw materials to delivery, enhancing risk resistance and ensuring stable delivery [7] Supply Side: Industry Outlook Attracting Capital - The high-throughput DNA synthesis market has seen over twelve companies emerge, with intense price competition and rapid cost declines [8] - The market capacity is projected to be between 100-150 million RMB by 2025, with potential demand growth offset by rapid price declines [8] Core Technology Deep Self-Research - The company has developed a high-throughput synthesis platform from scratch, continuously optimizing key processes to ensure quality while optimizing costs [9] Ignite 3.0: Reducing Burden and Accelerating Innovation - The company has launched the Ignite 3.0 platform, designed to address core industry pain points and enhance the development of synthetic biology [10] - Ignite 3.0 integrates high throughput, quality, and short cycles, supporting oligo pools of varying sizes and achieving a low error rate of below 0.2% [11] Performance Data Evidence - The platform can synthesize 680,000 independent points in a single run, with a synthesis length of up to 200nt and a coverage rate exceeding 99.9% [12] - The uniformity of the synthesized products is demonstrated with a 95/5 percentile ratio of 1.82, ensuring equal sampling in downstream screening [14] Future Prospects: Open Experience - Ignite 3.0 is not just a synthesizer but a validated "full-process solution," with high-quality oligo pools already showing strong competitiveness in various fields [19] - The company invites research users to apply for testing the Ignite 3.0 platform, aiming to expand into high-throughput gene construction [19]